Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic NSCLC

Interventions

DRUG: Datopotamab deruxtecan
DRUG: Durvalumab
DRUG: Carboplatin
DRUG: AZD2936
DRUG: MEDI5752
DRUG: AZD7789

Sponsor

AstraZeneca

Collaborators

[object Object]